ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 133 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $214,000 | -95.4% | 18,200 | -96.0% | 0.00% | -95.7% |
| Q4 2018 | $4,618,000 | +852.2% | 450,500 | +1448.1% | 0.02% | +1050.0% |
| Q3 2018 | $485,000 | -75.2% | 29,100 | -76.5% | 0.00% | -75.0% |
| Q2 2018 | $1,956,000 | +43.6% | 123,800 | +11.4% | 0.01% | +33.3% |
| Q3 2017 | $1,362,000 | -55.9% | 111,146 | -58.8% | 0.01% | -64.7% |
| Q2 2017 | $3,089,000 | +162.7% | 269,800 | +472.8% | 0.02% | +112.5% |
| Q2 2016 | $1,176,000 | -95.8% | 47,100 | -95.9% | 0.01% | -96.3% |
| Q1 2016 | $28,257,000 | -33.4% | 1,153,800 | -10.1% | 0.22% | -38.0% |
| Q4 2015 | $42,404,000 | +8.8% | 1,283,800 | +7.9% | 0.35% | +14.4% |
| Q3 2015 | $38,975,000 | -10.2% | 1,189,700 | +45.2% | 0.31% | +1.7% |
| Q2 2015 | $43,404,000 | +258.7% | 819,400 | +95.5% | 0.30% | +267.1% |
| Q1 2015 | $12,099,000 | +4364.6% | 419,233 | +4407.9% | 0.08% | +4000.0% |
| Q4 2014 | $271,000 | – | 9,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,130 | $34,629,000 | 11.36% |
| Foresite Capital Management II, LLC | 1,586,220 | $18,670,000 | 10.50% |
| DAFNA Capital Management LLC | 636,013 | $7,486,000 | 2.81% |
| Redmile Group, LLC | 8,244,896 | $97,042,000 | 2.75% |
| Lion Point Capital, LP | 1,204,600 | $14,178,000 | 1.40% |
| Palo Alto Investors LP | 1,861,630 | $21,911,000 | 1.06% |
| SAMLYN CAPITAL, LLC | 3,517,856 | $41,405,000 | 0.87% |
| Bellevue Group AG | 4,118,806 | $48,478,000 | 0.83% |
| Rock Springs Capital Management LP | 1,562,300 | $18,388,000 | 0.66% |
| Artal Group S.A. | 850,000 | $10,005,000 | 0.40% |